Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Cancer is one of the major cause of death around the globe. From Wikipedia
The Phase 3 result positions the TROP2‑targeting ADC for regulatory filings, potentially shifting first‑line care for patients who cannot receive immunotherapy.
